Data from 44 pooled clinical practice studies were compared for epilepsy patients with focal-onset and/or generalised-onset seizures treated with perampanel (PER) monotherapy (n=268) (first-line or conversion to monotherapy). Retention was assessed after 3, 6 and 12 months of PER treatment. Seizure freedom rates and responder rates (≥50% seizure frequency reduction), assessed by seizure type at last visit were evaluated (last observation carried forward). Adverse events (AEs) and discontinuation due to AEs were evaluated. Seizure types at baseline were focal-onset only (75.0%), generalised-onset only (24.5%), and focal-onset and generalised-onset (0.5%). At 3, 6 and 12 months, retention rates were 91.1%, 87.3% and 73.3%, respectively. At last visit, seizure freedom rates in patients with focal-onset and generalised-onset seizures were 64.1% and 69.4%, respectively; corresponding responder rates were 84.4% and 93.9%, respec- tively. AEs were reported for 45.2% of patients, with the most frequent (≥10% of patients) being dizziness/vertigo (16.8%) and irritability (11.2%); 13.7% of patients discontinued due to AEs over 12 months. Psychiatric AEs were reported for 20.8% of patients. In conclusion, PER was effective and generally well-tolerated as monotherapy for focal-onset and/or generalised-onset seizures in everyday clinical practice. At last visit, approximately two-thirds of patients were seizure free.

Supported by Eisai